Please try another search
For the six months ended 30 June 2019, Elanix Biotechnologies AG revenues decreased 90% to EUR3K. Net loss decreased 74% to EUR609K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Administrative Expenses - other decrease of 83% to EUR222K (expense), Labor & Related Expenses in SGA decrease of 91% to EUR56K (expense).
Period Ending: | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Revenue | 0 | 0.03 | 0.03 | 0.15 |
Gross Profit | 0 | -0.14 | -0.08 | 0.03 |
Operating Income | -0.21 | -1.51 | -2.17 | -1.26 |
Net Income | -0.61 | -1.43 | -2.3 | -1.32 |
Period Ending: | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Total Assets | 0.59 | 1.08 | 21.57 | 22.42 |
Total Liabilities | 2.6 | 2.48 | 6.32 | 6.39 |
Total Equity | -2.01 | -1.4 | 15.25 | 16.03 |
Period Ending: | Jun 30, 2019 | Dec 31, 2018 | Jun 30, 2018 | Dec 31, 2017 |
---|---|---|---|---|
Period Length: | 6 Months | 0 Months | 0 Months | 12 Months |
Cash From Operating Activities | -0.15 | -3.77 | ||
Cash From Investing Activities | 0 | -0.04 | ||
Cash From Financing Activities | 0.17 | 3.95 | ||
Net Change in Cash | 0.02 | 0.14 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review